373 related articles for article (PubMed ID: 15113815)
41. Identification and validation of an ERBB2 gene expression signature in breast cancers.
Bertucci F; Borie N; Ginestier C; Groulet A; Charafe-Jauffret E; Adélaïde J; Geneix J; Bachelart L; Finetti P; Koki A; Hermitte F; Hassoun J; Debono S; Viens P; Fert V; Jacquemier J; Birnbaum D
Oncogene; 2004 Apr; 23(14):2564-75. PubMed ID: 14743203
[TBL] [Abstract][Full Text] [Related]
42. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
43. [Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center].
Ngo C; Laé M; Ratour J; Hamel F; Taris C; Caly M; Le Cunff A; Reyal F; Kirova Y; Pierga JY; Vincent-Salomon A
Bull Cancer; 2017; 104(7-8):608-617. PubMed ID: 28595742
[TBL] [Abstract][Full Text] [Related]
44. Recent trends of HER-2 testing and trastuzumab therapy for breast cancer.
Kurosumi M
Breast Cancer; 2009; 16(4):284-7. PubMed ID: 19657709
[TBL] [Abstract][Full Text] [Related]
45. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of HER2/neu Status by Immunohistochemistry Using Computer-Based Image Analysis and Correlation With Gene Amplification by Fluorescence In Situ Hybridization Assay: A 10-Year Experience and Impact of Test Standardization on Concordance Rate.
Sarode VR; Xiang QD; Christie A; Collins R; Rao R; Leitch AM; Euhus D; Haley B
Arch Pathol Lab Med; 2015 Jul; 139(7):922-8. PubMed ID: 26125432
[TBL] [Abstract][Full Text] [Related]
47. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
48. Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.
Boulos F; Farra CG; Saad Aldin EM; Masaad C; Hassoun Y; Fedda F; Doumiati H; Tawil AN; Nasser Z; Nahleh Z; Tfayli A
J Clin Pathol; 2014 Mar; 67(3):204-9. PubMed ID: 24108431
[TBL] [Abstract][Full Text] [Related]
49. [HER-2 diagnostics].
Bánkfalvi A
Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
Mass RD; Press MF; Anderson S; Cobleigh MA; Vogel CL; Dybdal N; Leiberman G; Slamon DJ
Clin Breast Cancer; 2005 Aug; 6(3):240-6. PubMed ID: 16137435
[TBL] [Abstract][Full Text] [Related]
51. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
[TBL] [Abstract][Full Text] [Related]
52. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
Tanner M; Gancberg D; Di Leo A; Larsimont D; Rouas G; Piccart MJ; Isola J
Am J Pathol; 2000 Nov; 157(5):1467-72. PubMed ID: 11073807
[TBL] [Abstract][Full Text] [Related]
53. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
[TBL] [Abstract][Full Text] [Related]
54. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
55. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
Perez EA; Suman VJ; Davidson NE; Martino S; Kaufman PA; Lingle WL; Flynn PJ; Ingle JN; Visscher D; Jenkins RB
J Clin Oncol; 2006 Jul; 24(19):3032-8. PubMed ID: 16809727
[TBL] [Abstract][Full Text] [Related]
56. [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].
Fernö M; Haglund M; Bendahl PO; Olsson H; Rydén L
Lakartidningen; 2008 Aug 6-19; 105(32-33):2181-4. PubMed ID: 18780693
[No Abstract] [Full Text] [Related]
57. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
[TBL] [Abstract][Full Text] [Related]
58. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
[TBL] [Abstract][Full Text] [Related]
59. The need for a quality control of the whole process of immunohistochemistry human epidermal growth factor receptor 2/neu determination: a United Kingdom National External Quality Assessment Service/Italian Network for Quality Assessment of Tumor Biomarkers pilot experience.
Paradiso A; Miller K; Marubini E; Pizzamiglio S; Verderio P
J Clin Oncol; 2007 Aug; 25(22):e27-8. PubMed ID: 17664462
[No Abstract] [Full Text] [Related]
60. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.
Jacobs TW; Gown AM; Yaziji H; Barnes MJ; Schnitt SJ
J Clin Oncol; 1999 Jul; 17(7):1974-82. PubMed ID: 10561247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]